NasdaqGS - Nasdaq Real Time Price USD

Exelixis, Inc. (EXEL)

Compare

36.02

+1.52

+(4.41%)

At close: January 10 at 4:00:02 PM EST

36.00

-0.02

(-0.06%)

After hours: January 10 at 7:57:55 PM EST

FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib

EXEL's sNDA seeking approval of cabozantinib for the treatment of pancreatic neuroendocrine tumors will not be discussed at an ODAC.

Zacks yesterday

EXEL
+4.41%
Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors

ALAMEDA, Calif., January 09, 2025--Exelixis, Inc. (Nasdaq: EXEL) today announced it has been notified by the U.S. Food and Drug Administration (FDA) that the supplemental New Drug Application (sNDA) for cabozantinib (CABOMETYX®) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic (epNET) will no longer be the subject of discussion at an Oncologic Drugs Advisory Committee meeting. The sNDA remains under consideration b

Business Wire 2 days ago

EXEL
+4.41%
Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

ALAMEDA, Calif., January 06, 2025--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 5:15 p.m. PT / 8:15 p.m. PT.

Business Wire 5 days ago

EXEL
+4.41%
Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth?

EXEL's shares surge 50% in a year on the back of the strong performance of its lead drug Cabometyx. We are optimistic about the stock as we believe there is room for further growth.

Zacks 5 days ago

EXEL
+4.41%
Exelixis price target raised to $38 from $34 at RBC Capital

RBC Capital raised the firm’s price target on Exelixis (EXEL) to $38 from $34 and keeps an Outperform rating on the shares. Zanzalintinib stands out as Exelixis’ most clinically advanced asset with potential to become a primary contributor in the medium to long term, says the analyst, who is incorporating zanza into the firm’s valuation. The firm sees the nearest opportunity in metastatic colorectal cancer and incorporates the valuation in mCRC into its model at a 40% odds of success, the analys

TipRanks 11 days ago

EXEL
+4.41%
High Growth Tech Stocks to Watch in December 2024

The United States market has been flat over the last week but is up 24% over the past year, with earnings forecast to grow by 15% annually. In this context of robust growth expectations, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability in a rapidly evolving industry landscape.

Simply Wall St. 12 days ago

IBRX

EXEL
+4.41%
MVIS
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks 15 days ago

EXEL
+4.41%
EXEL vs. INCY: Which Stock Should Value Investors Buy Now?

EXEL vs. INCY: Which Stock Is the Better Value Option?

Zacks 17 days ago

INCY
-3.54%
EXEL
+4.41%
Is Exelixis, Inc. (EXEL) the Best Performing Biotech Stock in 2024?

We recently compiled a list of the 10 Best Performing Biotech Stocks in 2024. In this article, we are going to take a look at where Exelixis, Inc. (NASDAQ:EXEL) stands against the other biotech stocks. The Booming Biotechnology Sector The biotechnology sector is expanding quickly due to rising demand for novel therapies, advancement in technology, and […]

Insider Monkey 19 days ago

EXEL
+4.41%
The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam

Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam are included in this Analyst Blog.

Zacks 22 days ago

EXEL
+4.41%
ALNY
-1.07%
SRPT
-1.17%
4 Biotech Stocks Most Wall Street Analysts Are Bullish About

Here, we present four biotech stocks, namely SRPT, ADMA, EXEL and ALNY, which most Wall Street analysts are optimistic about. These companies have upside potential for 2025, backed by strong fundamentals.

Zacks 23 days ago

EXEL
+4.41%
ALNY
-1.07%
SRPT
-1.17%
Pfizer Stock Up 5% as 2025 Guidance Meets Investor Expectations

Pfizer projects total revenues between $61.0 and $64.0 billion with EPS in the range of $2.80 to $3.00.

Zacks 24 days ago

PFE

EXEL
+4.41%
NVS
Exelixis Risk/Reward Now 'More Balanced' With 2025 Catalysts Priced In, BofA Says

Exelixis' (EXEL) risks and reward now look "more balanced" following the stock's recent 37% gain dri

PREMIUM
MT Newswires 25 days ago

EXEL
+4.41%
SpringWorks Therapeutics (SWTX) Up 14.5% Since Last Earnings Report: Can It Continue?

SpringWorks Therapeutics (SWTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 30 days ago

EXEL
+4.41%
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks last month

EXEL
+4.41%
Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why

Exelixis (EXEL) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks last month

EXEL
+4.41%
EXEL or INCY: Which Is the Better Value Stock Right Now?

EXEL vs. INCY: Which Stock Is the Better Value Option?

Zacks last month

INCY
-3.54%
EXEL
+4.41%
AZN's Bladder Cancer sBLA for Imfinzi Gets FDA's Priority Tag

FDA grants priority review to AZN's sBLA seeking expanded use of Imfinzi for muscle-invasive bladder cancer.

Zacks last month

AZN

PFE

EXEL
+4.41%
2 Biotech Stocks to Buy Hand Over Fist in December

The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, an industry benchmark, is up 9% this year compared to 28% for the S&P 500. Despite moving in opposite directions in 2024, CRISPR Therapeutics and Exelixis have strong prospects.

Motley Fool last month

EXEL
+4.41%
CRSP

^GSPC
Acadia (ACAD) Down 2.9% Since Last Earnings Report: Can It Rebound?

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks last month

EXEL
+4.41%

Performance Overview

Return	EXEL	S&P 500
YTD	+6.88%	-1.35%
1-Year	+54.79%	+22.51%
3-Year	+92.21%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Exelixis, Inc. (EXEL)

FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib

Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors

Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth?

Exelixis price target raised to $38 from $34 at RBC Capital

High Growth Tech Stocks to Watch in December 2024

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

EXEL vs. INCY: Which Stock Should Value Investors Buy Now?

Is Exelixis, Inc. (EXEL) the Best Performing Biotech Stock in 2024?

The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam

4 Biotech Stocks Most Wall Street Analysts Are Bullish About

Pfizer Stock Up 5% as 2025 Guidance Meets Investor Expectations

Exelixis Risk/Reward Now 'More Balanced' With 2025 Catalysts Priced In, BofA Says

SpringWorks Therapeutics (SWTX) Up 14.5% Since Last Earnings Report: Can It Continue?

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why

EXEL or INCY: Which Is the Better Value Stock Right Now?

AZN's Bladder Cancer sBLA for Imfinzi Gets FDA's Priority Tag

2 Biotech Stocks to Buy Hand Over Fist in December

Acadia (ACAD) Down 2.9% Since Last Earnings Report: Can It Rebound?

Performance Overview